Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will today present positive data from its Phase II study of LEVI-04 in ...

Cambridge, UK, 24 th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the ...

The Geneva College of Longevity Science (GCLS) today announced the launch of the world’s first PhD in Medicine with a specialization in Longevity Sciences, developed in academic partnership with ...

IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 –IBA (Ion Beam App ...

Coartem Baby was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica consortium, which is co-funded by the European & Developing Countries Clinical ...

Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2026.

CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines ...

Groundbreaking AAV-based gene therapy offers potential treatment for patients with OTOF gene-associated severe-to-profound and profound hearing loss. White Oak, Md., April 24, 202 ...

If the Company does not regain compliance with the Minimum Bid Price Rule by October 19, 2026, Nasdaq has informed the Company that it will provide written notification that the Company’s Class A ...

Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it ...

Total VITAS admissions increased 6.9% in the first quarter of 2026 compared to the first quarter of 2025. In the first quarter of 2026, VITAS accrued $2.4 million in Medicare Cap billing limitation.